论文信息 - A phase I study evaluating GDC-0941, an oral phosphoinositide-3 kinase (PI3K) inhibitor, in patients with advanced solid tumors or multiple myeloma. - 字舞流文

A phase I study evaluating GDC-0941, an oral phosphoinositide-3 kinase (PI3K) inhibitor, in patients with advanced solid tumors or multiple myeloma.

J. Ware | N. Tunariu | H. Koeppen | J. D. de Bono | G. Levy | D. Sarker | R. Baird | K. Shah | K. Mazina | D. Papadatos-Pastos | D. Papadatos-Pastos | A. Omlin | A. Biondo | B. Basu | V. Moreno García | M. Puglisi | P. Cassier | M. Blanco | J. Pedersen